The antibody-drug conjugate (ADC) market continues to attract strong investor interest. Barcelona-based biotech company Ona Therapeutics has now secured $86.6 million in Series B financing to advance its innovative cancer treatment pipeline. The funding will support the development of two first-in-class ADC candidates designed to combat treatment-resistant cancers, particularly breast and colorectal tumors.
As cancer therapies evolve, biotechnology companies are searching for more effective ways to target resistant tumors. Consequently, Ona Therapeutics is positioning itself as a key player in the rapidly growing ADC landscape.
Ona Therapeutics Secures Major Funding
Ona Therapeutics announced the successful completion of an oversubscribed Series B financing round worth approximately $87 million. The investment was co-led by Columbus Venture Partners and Mérieux Equity Partners, with participation from several new and existing investors. The funding marks a significant milestone as the company transitions from a research-focused biotech into a clinical-stage organization.
Importantly, the capital will accelerate clinical development activities and help advance multiple pipeline programs toward human trials. Furthermore, the financing strengthens Ona’s ability to maintain worldwide commercial rights to its innovative therapies.
Why ADCs Are Transforming Cancer Treatment
Understanding Antibody-Drug Conjugates
Antibody-drug conjugates combine the precision of antibodies with the cancer-killing power of potent therapeutic payloads. These targeted therapies deliver toxic agents directly to cancer cells while minimizing damage to healthy tissues.
Over the past few years, ADCs have become one of the most promising areas in oncology. More than 20 ADC therapies have already received regulatory approval across various cancer indications. In addition, leading products such as Enhertu have demonstrated the commercial and clinical potential of this treatment category.
Growing Need for Better Cancer Therapies
Despite advances in cancer treatment, many patients eventually develop resistance to existing therapies. As a result, physicians face significant challenges when treating advanced-stage disease.
Ona Therapeutics aims to solve this problem by identifying novel targets associated with cancer progression and treatment resistance. The company believes this strategy could improve outcomes for patients who have exhausted current treatment options.
Ona’s Differentiated Approach to Drug Resistance
Unlike many ADC developers that focus on new payloads or linker technologies, Ona Therapeutics is concentrating on novel biological targets. The company uses a proprietary patient-driven discovery platform to identify tumor-specific antigens linked to resistant cancers.
This strategy enables researchers to target cancer cells that survive traditional treatments. Therefore, patients may achieve deeper and longer-lasting responses.
Moreover, the company carefully selects targets that appear predominantly in cancer cells and remain minimally expressed in healthy tissue. This approach could potentially improve therapeutic effectiveness while reducing toxicity.
Key Pipeline Programs: ONA-255 and ONA-389
ONA-255 for Breast Cancer
Ona’s lead candidate, ONA-255, is a first-in-class ADC initially focused on hormone receptor-positive, HER2-negative metastatic breast cancer. This subtype represents a large percentage of advanced breast cancer cases worldwide.
Although patients currently receive hormone therapies and CDK4/6 inhibitors, treatment options become limited once those therapies stop working. Consequently, ONA-255 could address a significant unmet medical need.
The company plans to move ONA-255 toward clinical proof of concept and begin human studies in the near future.
ONA-389 for Colorectal Cancer
Ona is also advancing ONA-389, a second ADC program targeting colorectal cancer. The therapy focuses on treatment-resistant disease and is progressing toward first-in-human clinical studies.
Together, ONA-255 and ONA-389 form the foundation of Ona’s long-term growth strategy in oncology.
Investor Confidence in the ADC Market
The successful financing round highlights continued enthusiasm for innovative oncology companies. Investors increasingly recognize the value of targeted therapies that address drug resistance and advanced cancer biology.
Additionally, industry experts believe Ona’s scientific approach differentiates it from many emerging ADC developers. The company’s experienced leadership team and strong preclinical data have further strengthened investor confidence.
Future Outlook for Ona Therapeutics
As the ADC market expands, Ona Therapeutics is entering an important phase of development. The newly secured funding will support clinical trials, regulatory milestones, and broader pipeline advancement.
Looking ahead, successful clinical results could establish the company as a leader in next-generation oncology therapeutics. More importantly, patients with treatment-resistant cancers may gain access to new therapeutic options that address a critical unmet need.
Conclusion
Ona Therapeutics’ $87 million Series B financing represents a major step forward in the fight against treatment-resistant cancers. By focusing on novel targets and first-in-class ADC therapies, the company hopes to improve outcomes for patients with advanced breast and colorectal cancers. If its clinical programs succeed, Ona could become a significant force in the evolving ADC market while delivering meaningful benefits to patients worldwide.
